Top 50 Companies in Liquid Biopsy Market in the World in 2025: Market Research Report (2024–2035)
RELEASE DATE: Jul 2025 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Description
According to a research report published by Spherical Insights & Consulting, The Global Liquid Biopsy Market Size is Projected to Grow from USD 10.60 Billion in 2024 to USD 31.70 Billion by 2035, at a CAGR of 11.58 % during the forecast period 2025–2035. The liquid biopsy market holds strong future opportunities in early cancer detection, monitoring minimal residual disease, personalized treatment planning, and non-invasive prenatal testing, driven by rising demand for precision and preventive diagnostics.
Introduction
The liquid biopsy market refers to a non-invasive diagnostic technology that analyzes biomarkers such as circulating tumor DNA (ctDNA), RNA, exosomes, and circulating tumor cells (CTCs) in bodily fluids—primarily blood. This method offers a real-time snapshot of a patient’s health and is increasingly used for early cancer detection, therapy selection, treatment monitoring, and relapse prediction. Key driving factors include the growing global burden of cancer, the rising demand for minimally invasive diagnostics, advancements in next-generation sequencing (NGS) and molecular testing technologies, and increasing adoption of personalized medicine. Additionally, its utility in early-stage cancer screening and recurrence tracking supports rapid market expansion.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights-Download the Brochure now and dive deeper into the future of the liquid biopsy market.
Liquid Biopsy Market Size & Statistics
The Market for Liquid Biopsy was estimated to be Worth USD 10.60 Billion in 2024.
The Market is Going to expand at a CAGR of 11.58 % between 2025 and 2035.
The Global Liquid Biopsy Market Size is anticipated to reach USD 31.70 Billion by 2035.
North America is expected to generate the highest demand during the forecast period in the liquid biopsy market.
Asia Pacific is expected to grow the fastest during the forecast period in the liquid biopsy market.
Regional growth and demand
Asia Pacific is expected to grow the fastest during the forecast period in the liquid biopsy market. The liquid biopsy market in the Asia-Pacific region is anticipated to grow the quickest in the forecast period, driven by the increasing incidence of cancer and an aging demographic, leading to a substantial need for precise monitoring and early detection solutions. Enhancing investments in healthcare infrastructure and research capabilities has enabled the integration of advanced medical technologies, such as liquid biopsy.
North America is expected to generate the highest demand during the forecast period in the liquid biopsy market. The region has a strong healthcare system and a significant understanding of the necessity for early cancer detection and tailored medicine. Major investments in R&D, coupled with the presence of leading biotechnology and pharmaceutical firms, have promoted the progress of liquid biopsy technologies. Furthermore, North America hosts various clinical trials and partnerships between academia and industry, fostering innovation and the commercialization of liquid biopsy products.
Top Key Drivers & Liquid Biopsy Trends
- Rising Prevalence of Cancer and Demand for Early Detection
One of the major drivers of the liquid biopsy market is the increasing global cancer burden. With millions of new cases diagnosed annually, the need for early, accurate, and minimally invasive diagnostics has surged. Liquid biopsies allow for early detection of cancer through blood samples, often before symptoms appear or tumors are detectable through imaging. This capability is crucial for improving survival rates and tailoring treatment plans. Compared to traditional biopsies, liquid biopsies offer a quicker, safer, and more patient-friendly method, making them an attractive option for both clinicians and patients across oncology care pathways.
- Technological Advancements in Genomics and Precision Medicine
Advancements in next-generation sequencing (NGS), digital PCR, and bioinformatics have significantly enhanced the sensitivity and accuracy of liquid biopsy tests. These technologies enable precise detection of genetic mutations, tumor heterogeneity, and resistance markers from a simple blood draw. This is propelling the shift toward precision oncology, where treatments are personalized based on a patient’s molecular profile. Integration of AI and cloud computing further supports large-scale data analysis, making liquid biopsy a scalable tool for population-level cancer screening and monitoring. These innovations are not only driving adoption in cancer but also expanding the market to include prenatal testing and transplant monitoring.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the liquid biopsy market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Top 5 Liquid Biopsy Startups Impacting Oncology
- Mursla – Exosome Quantum Sensing
Liquid biopsy utilizes various biomarkers for the diagnosis of conditions. In particular, investigating biomarkers like exosomes presents a path for liquid biopsy startups to create groundbreaking solutions. Exosomes originating from tumors have been shown to promote tumor growth and metastasis. UK startup Mursla introduces NPQuantumSense, an on-chip system for non-invasive cancer detection through the analysis of cancer-specific exosomes found in the bloodstream. This technology utilizes quantum effects in biofluids and relies on nanogap electrodes. Nanosensors are triggered when target biomarkers like exosomes are captured.
- Lucence – Circulating Tumor DNA
The tumor-derived DNA (ctDNA) found in the blood serves as a crucial biomarker for cancer detection and prognosis. This circulating DNA comes either from tumors or from tumor cells that are found in the bloodstream. Additionally, following the rupture of dead tumor cells, ctDNA may be released into the bloodstream. Lucence, a startup based in Singapore, has developed AmpliMARK, a unique sequencing technology that uses amplicons to identify genes associated with cancer and viruses. Through signal amplification, the startup can precisely identify cancer cells and genetic changes in cancer. Examining ctDNA allows for the detection of mutations in cancer tumors and assists in providing tailored cancer therapies.
- SmartCatch – Circulating Tumor Cells (CTC) Capture
The precision and particularity of diagnostic tests greatly rely on the quantity of biomarkers found in bodily fluids. Liquid biopsy biomarkers like CTCs exist at levels of 1–10 CTCs in 5ml of blood, complicating the early diagnosis of cancer—a challenge that leads to millions of lost lives each year. The French startup SmartCatch offers a CTC capture device that focuses on size and deformability. This device allows for the one-step physical capture of CTCs without the need for sample preparation. Consequently, there is little loss of clinically significant information in the liquid biopsy.
- Predicine – Circulating Free DNA & RNA
Circulating free DNA (cfDNA) and RNA (cfRNA) found in bodily fluids like blood or urine support the thorough characterization of cancer. The advancement of cancer at the DNA and RNA levels necessitates the examination of cfDNA and cfRNA for a comprehensive understanding of the illness. Predicine, a startup based in the US, has created GeneRADAR, a patented liquid biopsy test designed for early cancer detection, monitoring the disease, and evaluating residual disease. Their technology identifies cfDNA and cfRNA biomarkers to enhance the understanding of the disease's genomic profile and functional biology.
- GENECAST – High Detection Sensitivity
The prompt identification of cancer is crucial for lowering the death rate associated with this illness. To address this challenge, startups are concentrating not only on different types of novel cancer biomarkers but also on enhancing the sensitivity of existing liquid biopsy tests. The South Korean company GENECAST is developing the Allele-Discriminating Priming System (ADPS), a unique technology that boasts a maximum detection sensitivity of 0.0001%. The ADPS platform attains this sensitivity by selectively amplifying ctDNA with the company’s custom-engineered smart DNA polymerase.
Top 10 Companies Leading the Liquid Biopsy Market
- Bio-Rad Laboratories
- Biocept Inc.
- Guardant Health
- Illumina, Inc.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Laboratory Corporation of America Holdings
- MDxHealth SA
- QIAGEN N.V
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories
Headquarters: Hercules, California, USA
Bio-Rad Laboratories is a global leader in life sciences and clinical diagnostics. The company develops, manufactures, and markets a wide array of instruments, software, and consumables used for research and diagnostic testing. In the liquid biopsy market, Bio-Rad offers digital PCR technology that enables precise detection of rare genetic mutations in circulating tumor DNA (ctDNA). Its Droplet Digital PCR (ddPCR) platform is widely used in oncology, aiding early detection and monitoring of cancer. Bio-Rad’s commitment to innovation and quality makes it a preferred choice for researchers and clinicians focusing on molecular diagnostics and personalized medicine.
- Biocept Inc.
Headquarters: San Diego, California, USA
Biocept Inc. is a molecular diagnostics company specializing in liquid biopsy technologies for cancer detection and monitoring. The company focuses on the development of proprietary platforms to analyze circulating tumor cells (CTCs) and cell-free DNA (cfDNA) from blood samples. Its Target Selector™ assays are used to identify actionable genetic biomarkers, enabling personalized treatment strategies in oncology. Biocept serves both clinical and research markets, providing testing services through its CLIA-certified, CAP-accredited laboratory. With an emphasis on non-invasive cancer diagnostics, Biocept aims to improve patient outcomes through timely, targeted insights into tumor biology and therapeutic resistance.
- Guardant Health
Headquarters: Redwood City, California, USA
Guardant Health is a precision oncology company known for pioneering advanced liquid biopsy tests. Its flagship product, Guardant360®, is widely used for comprehensive genomic profiling of solid tumors using blood samples. The company also offers GuardantOMNI™ for clinical research and Guardant Reveal™ for minimal residual disease (MRD) detection. Guardant’s proprietary digital sequencing platform enables early cancer detection, real-time treatment monitoring, and recurrence prediction. Collaborating with biopharma companies, research institutions, and clinicians, Guardant Health is driving the shift toward non-invasive cancer care. Its mission is to conquer cancer through data-driven insights and accessible diagnostics.
- Illumina, Inc.
Headquarters: San Diego, California, USA
Illumina, Inc. is a global genomics leader that provides sequencing and array-based solutions for genetic analysis. While not exclusively a liquid biopsy company, Illumina’s next-generation sequencing (NGS) technology is foundational to many liquid biopsy platforms. Its instruments and reagents enable comprehensive genomic profiling of cell-free DNA (cfDNA) for cancer detection and monitoring. Illumina collaborates with diagnostics companies to power liquid biopsy tests used in oncology and reproductive health. Known for innovation, scalability, and accuracy, Illumina continues to advance precision medicine by making high-throughput, affordable sequencing accessible for research and clinical applications worldwide.
- F. Hoffmann-La Roche Ltd.
Headquarters: Basel, Switzerland
F. Hoffmann-La Roche Ltd., commonly known as Roche, is one of the world’s largest healthcare companies, with a strong focus on diagnostics and pharmaceuticals. In the liquid biopsy space, Roche offers cutting-edge solutions through its subsidiary Foundation Medicine and partnerships using NGS and ctDNA analysis. Roche’s AVENIO ctDNA assays provide non-invasive cancer detection and monitoring. The company integrates its diagnostic capabilities with therapeutic expertise, promoting personalized cancer care. With a legacy of innovation, global reach, and regulatory strength, Roche plays a critical role in expanding access to liquid biopsy technologies and advancing precision oncology.
Are you ready to discover more about the liquid biopsy market?
The report provides an in-depth analysis of the leading companies operating in the global liquid biopsy market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Company Profiles
- Bio-Rad Laboratories.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Biocept Inc.
- Guardant Health
- Illumina, Inc.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Laboratory Corporation of America Holdings
- MDxHealth SA
- QIAGEN N.V
- Thermo Fisher Scientific Inc.
Conclusion
The liquid biopsy market is rapidly transforming the diagnostic landscape with its non-invasive, real-time capabilities for detecting and monitoring cancer and other genetic conditions. Fueled by technological advancements in genomics and growing global awareness about early disease detection, the market is attracting significant investments and innovation. Major players and emerging startups are developing highly sensitive and specific platforms to address clinical challenges across oncology and prenatal care. As the demand for precision medicine and patient-centric diagnostics rises, liquid biopsy is poised to become a cornerstone of next-generation healthcare, offering transformative opportunities across research, diagnostics, and therapeutic decision-making.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?